(Q48037206)

7 February 2018

title

Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. (English)

1 reference

7 February 2018

0 references

7

1 reference

7 February 2018

Robin Fredric Anders

13

object named as

Anders RF

1 reference

7 February 2018

author name string

Pye D

1

1 reference

7 February 2018

Vandenberg KL

2

1 reference

7 February 2018

Dyer SL

3

1 reference

7 February 2018

Irving DO

4

1 reference

7 February 2018

Goss NH

5

1 reference

7 February 2018

Woodrow GC

6

1 reference

7 February 2018

Alving CR

8

1 reference

7 February 2018

Richards RL

9

1 reference

7 February 2018

Ballou WR

10

1 reference

7 February 2018

Wu MJ

11

1 reference

7 February 2018

Skoff K

12

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 June 1997

1 reference

7 February 2018

published in

Vaccine

1 reference

7 February 2018

volume

15

1 reference

7 February 2018

issue

9

1 reference

7 February 2018

page(s)

1017-1023

1 reference

7 February 2018

An epitope recognised by inhibitory monoclonal antibodies that react with a 51 kilodalton merozoite surface antigen in Plasmodium falciparum

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900289-7

7 January 2021

Merozoite surface antigen-I of plasmodium

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900289-7

7 January 2021

Proteins on the surface of the malaria parasite and cell invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900289-7

7 January 2021

Structural diversity in the 45-kilodalton merozoite surface antigen of Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900289-7

7 January 2021

Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900289-7

7 January 2021

Preparation of clinical grade proteins produced by recombinant DNA technologies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900289-7

7 January 2021

Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900289-7

7 January 2021

Liposomes as carriers of antigens and adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900289-7

7 January 2021

Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900289-7

7 January 2021

FOLLOW-UP STUDY ON ARMY PERSONNEL WHO RECEIVED ADJUVANT INFLUENZA VIRUS VACCINE 1951-1953

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900289-7

7 January 2021

Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900289-7

7 January 2021

10.1016/S0264-410X(96)00289-7

Identifiers

DOI

1 reference

7 February 2018

release_suopr5jv35eexolvd6yewjyx5e

Fatcat ID

0 references

1 reference

7 February 2018